Reviews
TACE Plus Immunotherapy Versus TACE Alone in Unresectable Hepatocellular Carcinoma
Trovato et alESMO gastrointestinal oncology

A systematic review and network meta-analysis evaluated the comparative efficacy and safety of combining transarterial chemoembolization (TACE) with immune checkpoint inhibitor (ICI)-based regimens versus TACE alone in unresectable hepatocellular carcinoma (uHCC). Five phase III randomly assigned trials involving 2,414 patients were included, with progression-free survival (PFS) designated as the primary endpoint.
Compared with TACE alone, TACE plus ICI-based strategies significantly improved PFS (hazard ratio [HR] 0.69, 95% confidence interval [CI] 0.63-0.77; fixed-effect model) and objective response rate (risk ratio [RR] 1.41, 95% CI 1.34-1.49). The pooled overall survival estimate favored combination therapy but did not reach statistical significance (HR 0.88, 95% CI 0.78-1.00). In the network meta-analysis, all regimens improved PFS versus TACE alone, and the P-score ranking for PFS identified atezolizumab plus bevacizumab plus TACE as the highest-ranked regimen (P-score 0.744). Subgroup analyses seemed to suggest that patients with an albumin-bilirubin (ALBI) score of 1 could derive greater PFS benefit than those with an ALBI score of 2 or higher (interaction P = 0.0003).
Combination therapy increased grade 3-4 treatment-related adverse events (RR 2.49), serious adverse events (RR 3.10), and treatment-emergent adverse events leading to death (RR 1.73). The authors concluded that immunotherapy-based treatments combined with TACE consistently improved disease control in uHCC, although the survival benefit appeared more modest, and noted that additional follow-up and head-to-head randomly assigned trials are needed to define the optimal systemic partner for TACE.
Key Takeaways
- Compared with TACE alone, TACE combined with immunotherapy-based regimens significantly improved progression-free survival (HR 0.69, 95% CI 0.63-0.77) and objective response rate (RR 1.41, 95% CI 1.34-1.49), while overall survival favored combination therapy without reaching statistical significance (HR 0.88, 95% CI 0.78-1.00).
- Combination therapy increased grade 3-4 treatment-related adverse events (RR 2.49), serious adverse events (RR 3.10), and treatment-emergent adverse events leading to death (RR 1.73).
- Atezolizumab plus bevacizumab plus TACE was identified as the highest-ranked regimen for progression-free survival (P-score 0.744), with subgroup analyses suggesting greater progression-free survival benefit in patients with an albumin-bilirubin score of 1 versus 2 or higher (interaction P = 0.0003).
Read the original sourceESMO gastrointestinal oncology
